Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Multiple Sclerosis
NCT07303790Phase 1Recruiting
- Sponsor
- Daishi Tian
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in multiple sclerosis (MS), sponsored by Daishi Tian. Primary endpoints: Dose-Limiting Toxicity Rate at 28 days and Adverse Events Rate at 15 years. Started Mar 2026; status: recruiting.
02
Drugs
GC012
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07303790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07303790.